Cartesian Therapeutics (RNAC) Return on Sales (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Return on Sales data on file, last reported at 3.27% in Q1 2026.

• Return on Sales for Q1 2026 came in at 3.27%, down 309.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.55% (up 156.0% YoY), and the FY2025 annual result was 3.26%, down 324.0% from the prior year.
• Return on Sales slipped to 3.27% in Q1 2026 per RNAC's latest filing, from 0.53% in the prior quarter.
• Over five years, Return on Sales peaked at 0.53% in Q4 2025 and troughed at 8.8% in Q2 2025.
• A 5-year average of 0.75% and a median of 0.02% in 2024 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2024 and 2025: Return on Sales soared 41 bps in 2024, then slumped 881 bps in 2025.
• A 5-year view of Return on Sales shows it stood at 0.0% in 2022, then sank by 6880 bps to 0.24% in 2023, then jumped by 173 bps to 0.17% in 2024, then surged by 207 bps to 0.53% in 2025, then tumbled by 712 bps to 3.27% in 2026.
• Business Quant data shows RNAC's Return on Sales at 3.27% in Q1 2026, 0.53% in Q4 2025, and 0.43% in Q3 2025.